ReviewExpert review of anti-infective therapy2008
Atazanavir: its role in HIV treatment.
Review in Expert review of anti-infective therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 46 citations in OpenAlex.
- Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.Acta diabetologica · 2015Trial
- Modulation of Macrophage Inflammatory Responses by UDP-Glucuronosyltransferase-Mediated PGEJournal of personalized medicine · 2026Article
- High Prevalence of Severe Depression in Mexican Patients Diagnosed with HIV Treated with Efavirenz and Atazanavir: Clinical Follow-Up at Four Weeks and Analysis of TPH2 SNPs.Journal of clinical medicine · 2024Article
- In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs.International journal of molecular sciences · 2022Article
- Developing New Treatments for COVID-19 through Dual-Action Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based Pharmacokinetic Modeling.International journal of molecular sciences · 2022Review
- Review
- Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.Contraception · 2022Article
- Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 MPharmaceuticals (Basel, Switzerland) · 2021Article
- Development of a Bio-Layer Interferometry-Based Protease Assay Using HIV-1 Protease as a Model.Viruses · 2021Article
- DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease.Journal of molecular structure · 2021Article
- Identifying side effects of commonly used drugs in the treatment of Covid 19.Scientific reports · 2020Review
- HIV and kidney diseases: 35 years of history and consequences.Clinical kidney journal · 2016Review
- Article
- Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Journal of virology · 2014Article
- Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.AIDS research and human retroviruses · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Azatanavir is a protease inhibitor (PI) approved for the treatment of HIV-1 infection. Atazanavir is a substrate and inhibitor of cytochrome P450 isozyme 3A and an inhibitor and inducer of P-glycoprotein. It has similar virologic efficacy as efavirenz and ritonavir-boosted lopinavir in antiretroviral-naive individuals. Its impact on lipids is less than other PIs and it is suitable for those in whom hyperlipidemia is undesirable. Ritonavir boosting of atazanavir enhances the bioavailability of atazanavir but may result in some elevation of lipids and is recommended for treatment-experienced patients and those receiving efavirenz or tenofovir. Ritonavir-boosted atazanavir has similar antiviral activity as ritonavir-boosted lopinavir in both antiretroviral therapy-naive and -experienced patients. Atazanavir causes unconjugated bilirubinemia in over 40% of patients but results in less than 2% discontinuations. Atazanavir is licensed for once-daily use and atazanavir/ritonavir competes with lopinavir/ritonavir as the most commonly prescribed PI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.